Harnessing Preoperative Immunotherapy: A Step-by-Step Guide to the Colon Cancer Breakthrough with Pembrolizumab

By ✦ min read

Overview

A recent UK-led clinical trial has unveiled a paradigm-shifting treatment approach for a specific subset of colorectal cancer patients. Instead of the traditional sequence—surgery followed by months of chemotherapy—this new protocol delivers a short, nine-week burst of the immunotherapy drug pembrolizumab (Keytruda) before surgery. The results are striking: nearly three years after the procedure, patients remain cancer-free. This guide translates the trial's key findings into a practical, step-by-step roadmap for clinicians and researchers, covering patient selection, treatment administration, surgical timing, and long-term monitoring.

Prerequisites

Understanding the Target Population

The breakthrough applies specifically to patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer. These tumors have a high mutational burden, making them particularly susceptible to immune checkpoint inhibitors like pembrolizumab.

Required Diagnostic Testing

• Biomarker assessment: Confirm dMMR via immunohistochemistry (IHC) for MLH1, MSH2, MSH6, and PMS2 proteins, or MSI-H via polymerase chain reaction (PCR)-based microsatellite analysis.
• Staging workup: Complete colonoscopy, CT scan of chest/abdomen/pelvis, and CEA levels to ensure resectable, non-metastatic disease.
• Patient fitness: Adequate organ function (especially liver, kidney, bone marrow) and ECOG performance status ≤ 1. Exclude active autoimmune disease or prior immune-related adverse events.

Step-by-Step Implementation

Step 1: Patient Enrollment and Informed Consent

Discuss with the patient the rationale for neoadjuvant immunotherapy vs. standard chemotherapy. Explain that the goal is to reduce tumor burden before surgery and potentially eliminate micrometastases, with the hope of avoiding adjuvant chemotherapy altogether. Obtain written consent for pembrolizumab 200 mg IV every 3 weeks for a total of three doses (covering 9 weeks).

Step 2: Administer Preoperative Immunotherapy

1. Premedication: Consider acetaminophen and antihistamines if prior infusion reactions. No routine steroids required.
2. Infusion protocol: Pembrolizumab diluted in 0.9% NaCl or D5W to a final concentration of 1–10 mg/mL. Infuse over 30 minutes through a 0.2–5 micron in-line filter.
3. Monitoring: Observe for infusion-related reactions during and for 30 minutes after. Document any immune-related adverse events (irAEs) such as rash, colitis, pneumonitis, or hepatitis.
4. Repeat doses: Administer every 21 days for a total of 3 cycles. Adjust schedule only for grade ≥3 irAEs as per institutional guidelines.

Example treatment plan: Day 1, Day 22, Day 43 of pembrolizumab. Surgery scheduled for approximately Day 50–60 (i.e., 1–2 weeks after last infusion).

Step 3: Timing of Surgery

Surgery should be performed 1–2 weeks after the last pembrolizumab dose to allow for maximal immune-mediated tumor shrinkage while minimizing surgical delay. The trial demonstrated that the optimal window yields a high pathologic complete response (pCR) rate. Perform standard oncologic resection with lymphadenectomy. Mark the specimen for pathologic evaluation of tumor regression grade (TRG).

Step 4: Postoperative Management

• Pathology report: Assess for pCR (no viable tumor cells). If pCR is achieved, no adjuvant chemotherapy is needed—this is the key departure from standard practice.
• Surveillance: Every 3 months for first 2 years: physical exam, CEA, CT chest/abdomen/pelvis. Then every 6 months for up to 5 years, then annually.
• Manage irAEs: Continue to monitor for delayed immune toxicities (e.g., hypothyroidism, adrenal insufficiency). Refer to endocrinology if needed.

Common Mistakes and Pitfalls

Mistake 1: Using Pembrolizumab in MSS/MSI-Low Tumors

Patients with microsatellite stable (MSS) or MSI-low tumors derive minimal benefit from checkpoint inhibitors. Biomarker testing must be completed before initiating neoadjuvant immunotherapy.

Mistake 2: Extending Immunotherapy Beyond 9 Weeks

The trial protocol specifically used three doses (9 weeks). Prolonging therapy may delay surgery and increase toxicity without proven additional benefit. Stick to the nine-week schedule.

Mistake 3: Delaying Surgery Due to Minor IrAEs

Grade 1–2 irAEs (e.g., mild rash, low-grade fever) should not postpone surgery. Manage symptomatically and proceed with planned resection. Only grade ≥3 toxicities (e.g., severe colitis, pneumonitis) warrant delay; in such cases, use corticosteroids and reschedule surgery after toxicity resolves to ≤ grade 1.

Mistake 4: Omitting Post-Surgery Surveillance

Even with pCR, long-term follow-up is critical. Nearly 3 years cancer-free is impressive, but recurrences after 3 years have been reported. Continue surveillance as per guidelines.

Summary

This novel neoadjuvant immunotherapy protocol—three doses of pembrolizumab followed by surgery—transforms the treatment landscape for dMMR/MSI-H colorectal cancer. By achieving durable remission without adjuvant chemotherapy, it reduces toxicity while maintaining excellent oncologic outcomes. Adoption requires strict patient selection via biomarker testing, precise scheduling, and vigilant monitoring for immune-related adverse events. As the trial's nearly three-year cancer-free data suggest, this approach may become a new standard of care.